TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15089065

Group type: COMPARATOR
Intervention: Normal saline (n = 31)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ondansetron (0.15 mg/kg, n = 39)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone (0.15 mg/kg ondansetron and 0.2 mg/kg dexamethasone, n = 30)
Number of subjects: 100
Study: 10891023

Group type: EXPERIMENTAL
Intervention: Psychological questionnaires administered at baseline to parents and participants
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Impact on Family Scale
Number of subjects: 1041
Study: 8629671

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWHs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study: 1634029

Group type: COMPARATOR
Intervention: Shorter appointment times
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer appointment times
Number of subjects: 0
Study: 6441236

Group type: EXPERIMENTAL
Intervention: Erythromycin base
Number of subjects: 100

Group type: COMPARATOR
Intervention: Phenoxymethyl-penicillin (penicillin V)
Number of subjects: 100
Study: 30684601

Group type: EXPERIMENTAL
Intervention: SEMS with tricuspid antireflux valve (SEMS-V)
Number of subjects: 60

Group type: COMPARATOR
Intervention: SEMS without valve (SEMS-NV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: SEMS-NV
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SEMS-V
Number of subjects: 60
Study: 29914441

Group type: EXPERIMENTAL
Intervention: Peer-led training
Number of subjects: 72

Group type: COMPARATOR
Intervention: Professional-led training
Number of subjects: 72
Study: 27671982

Group type: EXPERIMENTAL
Intervention: Mouthrinse water at 10°C
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mouthrinse water at 20°C
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mouthrinse water at 30°C
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Collection time (1-6 min)
Number of subjects: 10
Study: 24662422

Group type: EXPERIMENTAL
Intervention: Ready-to-feed (RTF) formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Powdered (PWD) formula
Number of subjects: 0
Study: 23949586

Group type: EXPERIMENTAL
Intervention: Vaginal suppository (metronidazole 750 mg/miconazole nitrate 200 mg) twice a day for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral metronidazole 2 g single dose
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vaginal suppository (metronidazole 750 mg/miconazole nitrate 200 mg) once a day for 7 days
Number of subjects: 40
Study: 20075691

Group type: EXPERIMENTAL
Intervention: Cool gel wrap and leg elevation intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Leg elevation alone intervention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Reactive recruitment strategies
Number of subjects: 60

Group type: COMPARATOR
Intervention: Proactive recruitment strategies
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Recruitment cost
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Time spent by principal investigator
Number of subjects: 60
Study: 17974502

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring receipt and proficiency training on its use and the Group Health secure patient website (with secure e-mail access to their healthcare provider, access to a shared medical record, prescription refill and other services)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: This plus pharmacist care management (collaborative care management between the patient, the pharmacist, and the patient's physician via a secure patient website and the electronic medical record)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 15915035

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nefopam and Ketoprofen combination
Number of subjects: 72
Study: 13130407

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (300 mg tablet once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 0
Study: 10995520

Group type: EXPERIMENTAL
Intervention: Spironolactone added to standard multidrug therapy (ACE inhibitor and loop diuretic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard multidrug therapy (ACE inhibitor and loop diuretic)
Number of subjects: 0
Study: 8637535

Group type: EXPERIMENTAL
Intervention: Testosterone (600 mg of testosterone enanthate weekly for 10 weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Testosterone plus exercise
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (no exercise)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo plus exercise
Number of subjects: 43
Study: 1323624

Group type: EXPERIMENTAL
Intervention: Foscarnet therapy (60 mg/kg every 8 h)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Foscarnet maintenance therapy
Number of subjects: 22
Study: 6437575

Group type: EXPERIMENTAL
Intervention: Mild surface cooling at 24 degrees C for 6 hours
Number of subjects: 0
Study: 30949685

Group type: EXPERIMENTAL
Intervention: Plasma 25-hydroxyvitamin D concentration (25(OH)D)
Number of subjects: 2185
Study: 30545387

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow concentrate (BMC) and platelet products
Number of subjects: 48

Group type: COMPARATOR
Intervention: Exercise therapy (control group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Crossover group (after 3 months of exercise therapy)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BMC treatment (after crossover)
Number of subjects: 48
Study: 26750669

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 mcg/kg, iv) + midazolam (0.5 mg, iv)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Propofol (1 mg/kg, iv) + midazolam (0.5 mg, iv)
Number of subjects: 44
Study: 24762111

Group type: EXPERIMENTAL
Intervention: Seated saline suppression testing (SSST)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Recumbent saline suppression testing (RSST)
Number of subjects: 31
Study: 22321076

Group type: EXPERIMENTAL
Intervention: Airtraq optical laryngoscope
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional laryngoscopy
Number of subjects: 60
Study: 20598282

Group type: COMPARATOR
Intervention: Levonorgestrel intrauterine contraception recommendation for low socioeconomic status whites
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine contraception recommendation for low socioeconomic status Latinas
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine contraception recommendation for low socioeconomic status blacks
Number of subjects: 524
Study: 18614450

Group type: EXPERIMENTAL
Intervention: CBT intervention (6-month weekly group and individual sessions)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Support group (control condition)
Number of subjects: 44
Study: 16192837

Group type: EXPERIMENTAL
Intervention: St John's wort (LI 160)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12625572

Group type: EXPERIMENTAL
Intervention: Defibrinogenation therapy (BX group)
Number of subjects: 88

Group type: COMPARATOR
Intervention: High-dose steroid therapy (PSL group)
Number of subjects: 88
Study: 10587327

Group type: EXPERIMENTAL
Intervention: Rifabutin 300 mg and isoniazid 750 mg twice weekly for 3 months (group A)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rifabutin 600 mg and isoniazid 750 mg twice weekly for 3 months (group B)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Isoniazid 300 mg/day for 6 months (group C)
Number of subjects: 44
Study: 8100913

Group type: EXPERIMENTAL
Intervention: Intravenous CGRP (0.6 micrograms/min for 3 h per day on 5 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous CGRP
Number of subjects: 10
Study: 3734845

Group type: EXPERIMENTAL
Intervention: Human lymphoblastoid interferon (HLBI) 3 MU/m2, i.m. (weekly maintenance)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control observation (no interferon)
Number of subjects: 21
Study: 30064473

Group type: EXPERIMENTAL
Intervention: Educational workshops based on the Theory of Planned Behavior (TPB), conducted over 4 years with 2 workshops per year.
Number of subjects: 744

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 744
Study: 27653164

Group type: EXPERIMENTAL
Intervention: Zofenopril 30 mg plus Hydrochlorothiazide 12.5 mg
Number of subjects: 482

Group type: COMPARATOR
Intervention: Irbesartan 150 mg plus Hydrochlorothiazide 12.5 mg
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (Zofenopril plus Hydrochlorothiazide)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Ambulatory blood pressure monitoring (Irbesartan plus Hydrochlorothiazide)
Number of subjects: 482
Study: 25483553

Group type: EXPERIMENTAL
Intervention: Three kiwifruits a day for 8 weeks
Number of subjects: 118

Group type: COMPARATOR
Intervention: One apple a day for 8 weeks
Number of subjects: 118
Study: 23242248

Group type: EXPERIMENTAL
Intervention: Innovator cisplatin formulation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Generic cisplatin formulation
Number of subjects: 44
Study: 22017935

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 450
Study: 19353267

Group type: EXPERIMENTAL
Intervention: Five session integrated intervention designed to reduce gender-based violence and HIV risk behaviors
Number of subjects: 475

Group type: COMPARATOR
Intervention: Single 3-hour alcohol and HIV risk reduction session
Number of subjects: 475
Study: 17115880

Group type: EXPERIMENTAL
Intervention: Primary Intensive Care (PIC) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study: 15152886

Group type: EXPERIMENTAL
Intervention: Parental monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control for age, gender, drinking at baseline, and being in various high-risk situations
Number of subjects: 0
Study: 11182467

Group type: EXPERIMENTAL
Intervention: MRI volumetric measures of hippocampal volume
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Left hippocampal volume
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Right hippocampal volume
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hippocampal asymmetry
Number of subjects: 39
Study: 9817475

Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg test dose, followed by 12.5 mg 3 times daily for 24 hours and 25 mg 3 times daily for the next 24 hours)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Losartan (25 mg/day increased to 50 mg after 24 hours)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Captopril plus Furosemide (40 mg in the morning)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous ISDN only (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Captopril (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Captopril plus Furosemide (group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Losartan (group D)
Number of subjects: 60
Study: 8291700

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg long‐acting orally 12 h before surgery and 10 mg sublingually 1.5 h before surgery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg sublingually just before induction of anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: No nifedipine (control)
Number of subjects: 30
Study: 2557183

Group type: EXPERIMENTAL
Intervention: Pentagastrin (6 micrograms/kg, subcutaneously)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ranitidine (150 mg orally, 10 and 2 hours before dosing)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sodium bicarbonate (12.6 gm)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Aluminum hydroxide (120 cc)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High protein diet
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low protein diet
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High fat diet
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 33
Study: 28302116

Group type: EXPERIMENTAL
Intervention: e-learning training and education
Number of subjects: 247

Group type: COMPARATOR
Intervention: face-to-face group training
Number of subjects: 247

Group type: COMPARATOR
Intervention: regular care
Number of subjects: 247
Study: 25792492

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once weekly
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 23275593

Group type: EXPERIMENTAL
Intervention: APOE4 carriers
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-APOE4 controls
Number of subjects: 18
Study: 21984584

Group type: EXPERIMENTAL
Intervention: GIP infusion during hypoglycemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GIP infusion during euglycemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GIP infusion during hyperglycemia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion during hypoglycemia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion during euglycemia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion during hyperglycemia
Number of subjects: 10
Study: 18293187

Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 32
Study: 16501248

Group type: EXPERIMENTAL
Intervention: DNMT3b-c31721t SNP
Number of subjects: 9054

Group type: EXPERIMENTAL
Intervention: PRDM2-c99243 t SNP
Number of subjects: 9054

Group type: EXPERIMENTAL
Intervention: t105413c SNP
Number of subjects: 9054

Group type: EXPERIMENTAL
Intervention: EHMT1-g-9441a SNP
Number of subjects: 9054

Group type: EXPERIMENTAL
Intervention: EHMT1-g41451t SNP
Number of subjects: 9054

Group type: EXPERIMENTAL
Intervention: EHMT2-S237S SNP
Number of subjects: 9054

Group type: EXPERIMENTAL
Intervention: Overall significant SNPs
Number of subjects: 9054

Group type: EXPERIMENTAL
Intervention: Homozygotes for rare alleles of EHMT1, EHMT2, and PRDM2
Number of subjects: 9054
Study: 14511868

Group type: EXPERIMENTAL
Intervention: Epidural
Number of subjects: 128

Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 128

Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 128
Study: 10894313

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: No weight loss intervention (Control)
Number of subjects: 67
Study: 9362356

Group type: EXPERIMENTAL
Intervention: Intra-arterial injection of 131I-labeled Lipiodol (60 mCi; 2.2 GBq) (n = 73)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Chemoembolization (70 mg cisplatin) (n = 69)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Intra-arterial injection of 131I-labeled Lipiodol (n = 73)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Chemoembolization (n = 69)
Number of subjects: 142
Study: 8402090

Group type: EXPERIMENTAL
Intervention: Air plethysmography
Number of subjects: 113

Group type: COMPARATOR
Intervention: Ambulatory venous pressure measurement
Number of subjects: 113
Study: 3511878

Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Desipramine therapy after crossover from placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Overall improvement with desipramine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Global clinical status improvement
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Zung depression scores
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bulimia symptom scale
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Desipramine treatment
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: One-month follow-up data
Number of subjects: 22
Study: 29518488

Group type: EXPERIMENTAL
Intervention: Diet I - moderate in carbohydrate
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Diet II - normal in carbohydrate
Number of subjects: 280
Study: 27297936

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 220

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 220
Study: 24686885

Group type: EXPERIMENTAL
Intervention: Highest quartile of modelled CVD risk at baseline
Number of subjects: 2418

Group type: EXPERIMENTAL
Intervention: Lowest quartile of modelled CVD risk at baseline
Number of subjects: 2418

Group type: COMPARATOR
Intervention: Socioeconomic status
Number of subjects: 2418
Study: 22735175

Group type: EXPERIMENTAL
Intervention: Group cognitive behavior therapy (G-CBT) plus pharmacotherapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Treatment as usual (TAU; only pharmacotherapy)
Number of subjects: 41
Study: 20211300

Group type: EXPERIMENTAL
Intervention: Diffuse Symptoms cluster
Number of subjects: 3522

Group type: COMPARATOR
Intervention: Classic ACS, Pain Symptoms, Stress Symptoms clusters
Number of subjects: 3522
Study: 18622280

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 150
Study: 16135476

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for chronic insomnia
Number of subjects: 57

Group type: COMPARATOR
Intervention: Waiting-list control condition (WLC)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both treated groups (CBT and WLC)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Follow-up measures
Number of subjects: 57
Study: 11812507

Group type: EXPERIMENTAL
Intervention: High-yield non-menthol cigarettes
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Commercial cigarettes
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low-yield cigarettes
Number of subjects: 36

Group type: COMPARATOR
Intervention: Menthol and non-menthol cigarettes
Number of subjects: 36
Study: 10624328

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 102

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 102
Study: 7560222

Group type: EXPERIMENTAL
Intervention: Solution A (0.06% triclosan + 2% tween 80)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Solution B (0.06% triclosan + 0.25% sodium lauryl sulphate)
Number of subjects: 10
Study: 1935152

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (1 mmol/kg body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sodium chloride (control)
Number of subjects: 10
Study: 6991994

Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 36
Study: 31644515

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (DEX) 1.5 μg/kg
Number of subjects: 134

Group type: COMPARATOR
Intervention: Intranasal saline (Placebo)
Number of subjects: 134
Study: 31103605

Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy
Number of subjects: 0
Study: 27804204

Group type: EXPERIMENTAL
Intervention: Filter A: Poliflux®RevaclearMAX
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Filter B: Helixone®Fx80
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Filter C: Polyflux®H210
Number of subjects: 41
Study: 26452988

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1085
Study: 23565740

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Glimepiride (individually titrated up to 4 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both treatments (Vildagliptin and Glimepiride)
Number of subjects: 44
Study: 21098799

Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg bolus, 0.5 mg/kg top-up if needed) with fentanyl (3 μg/kg bolus)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam (0.1 mg/kg bolus, 0.1 mg/kg top-up if needed) with fentanyl (3 μg/kg bolus)
Number of subjects: 40
Study: 19245728

Group type: EXPERIMENTAL
Intervention: Helios oxygen system
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: HomeFill oxygen system
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: FreeStyle oxygen system
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Compressed-oxygen cylinder system
Number of subjects: 39
Study: 17084252

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 10001

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 10001
Study: 15126653

Group type: EXPERIMENTAL
Intervention: Embolotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 70
Study: 11487075

Group type: EXPERIMENTAL
Intervention: Laparoscopic varix ligation with internal spermatic artery (ISA) preservation (Group A)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Laparoscopic varix ligation with ISA ligation (Group B)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Laparoscopic varix ligation with ISA preservation (Group A)
Number of subjects: 25
Study: 9257379

Group type: EXPERIMENTAL
Intervention: Tretinoin cream 0.025% applied nightly
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo applied nightly
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tretinoin cream 0.025%
Number of subjects: 48
Study: 8302412

Group type: EXPERIMENTAL
Intervention: High flux hemodialysis
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional hemodialysis
Number of subjects: 21
Study: 3087310

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30883516

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) 5 mg/kg every 4 weeks for up to 20 weeks
Number of subjects: 47
Study: 29877964

Group type: EXPERIMENTAL
Intervention: ECT plus antipsychotic drugs (APD)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Antipsychotic drugs (APD) only
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined patient groups (ECT + APD and APD only)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy comparisons
Number of subjects: 31
Study: 27093702

Group type: EXPERIMENTAL
Intervention: SCIAN LD‐735 wrist blood pressure monitor
Number of subjects: 33
Study: 24930728

Group type: EXPERIMENTAL
Intervention: Losmapimod (7.5 mg or 15.0 mg loading dose followed by 7.5 mg twice daily)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 526